Wall Street analysts forecast that Pulse Biosciences Inc (NASDAQ:PLSE) will report earnings of ($0.51) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Pulse Biosciences’ earnings. Pulse Biosciences posted earnings of ($0.54) per share in the same quarter last year, which would suggest a positive year over year growth rate of 5.6%. The firm is scheduled to issue its next earnings report after the market closes on Tuesday, July 30th.

According to Zacks, analysts expect that Pulse Biosciences will report full year earnings of ($2.09) per share for the current year. For the next financial year, analysts expect that the firm will post earnings of ($2.10) per share. Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Pulse Biosciences.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Tuesday, April 30th. The company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.05).

Several equities research analysts recently weighed in on the company. ValuEngine raised Whiting Petroleum from a “strong sell” rating to a “sell” rating in a report on Friday, April 5th. HC Wainwright reaffirmed a “buy” rating on shares of Pulse Biosciences in a report on Wednesday, May 1st. Finally, BidaskClub downgraded Zebra Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers bought a new position in Pulse Biosciences during the fourth quarter valued at $159,000. Northern Trust Corp lifted its position in Pulse Biosciences by 10.2% during the fourth quarter. Northern Trust Corp now owns 121,031 shares of the company’s stock valued at $1,387,000 after purchasing an additional 11,212 shares during the last quarter. Geode Capital Management LLC lifted its position in Pulse Biosciences by 49.5% during the fourth quarter. Geode Capital Management LLC now owns 117,149 shares of the company’s stock valued at $1,342,000 after purchasing an additional 38,763 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in Pulse Biosciences by 1,082.7% during the first quarter. BNP Paribas Arbitrage SA now owns 2,259 shares of the company’s stock valued at $40,000 after purchasing an additional 2,068 shares during the last quarter. Finally, Griffin Asset Management Inc. bought a new position in Pulse Biosciences during the first quarter valued at $903,000. 9.09% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ PLSE traded up $0.49 during mid-day trading on Thursday, hitting $13.20. 44,402 shares of the company were exchanged, compared to its average volume of 33,935. The company has a debt-to-equity ratio of 0.02, a current ratio of 17.13 and a quick ratio of 17.13. The business’s 50 day moving average is $12.52. Pulse Biosciences has a 1-year low of $8.60 and a 1-year high of $19.77.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.

See Also: Dividend Achievers

Get a free copy of the Zacks research report on Pulse Biosciences (PLSE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.